Evaluation of Rhinological Symptoms and Quality of Life in Patients with Allergic or Eosinophilic Severe Uncontrolled Asthma Treated with Anti-IgE or Anti-IL5 Therapy: A Real-Live Study

Six-month phenotyping-based biological therapy with omalizumab in patients with chronic allergic rhinitis accompanied by several bronchial asthma or with mepolizumab in patients with chronic sinusitis with nasal polyps accompanied by several bronchial asthma showed significant improvement in rhinological symptoms and quality of life.